Clinical Trials Browser

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

Arteriovenous Malformations, Hemangioendothelioma, Hemangioma, Lymphangioma, Nevus, Vascular Malformations

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Endometrial Hyperplasia

Thyroid cancer, Hurthle cell

Endometrial Neoplasms

Carcinoma, Renal Cell, Kidney Neoplasms

Neoplasm Metastasis

Breast Neoplasms

Recurrence, Endometrial Neoplasms

Endometrial Neoplasms

Neoplasm Metastasis

Thyroid Diseases, Thyroid Neoplasms

Breast Neoplasms

Uterine Neoplasms, Endometrial Neoplasms

Carcinoma, Islet Cell, Carcinoma, Neuroendocrine

Mastocytosis, Systemic

Neoplasm Metastasis, Pancreatic Neoplasms

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Prostatic Neoplasms

Leiomyosarcoma, Liposarcoma, Sarcoma

Breast Neoplasms

Locally Advanced Thyroid Gland Carcinoma

Estrogen Receptor Positive Breast Cancer

Neuroendocrine Tumors

Breast Neoplasms

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

Neoplasms, Peutz-Jeghers Syndrome, Polyps

Breast Neoplasms

Carcinoma, Hepatocellular

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

Familial ependymoma, Ependymoma

Colonic Neoplasms

Neuroma, Acoustic, Neurofibromatosis 2

Triple Negative Breast Neoplasms

Breast Neoplasms

Carcinoma, Renal Cell, Kidney Neoplasms

Neurofibroma, Neurofibromatosis 1

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Breast Neoplasms

Breast Neoplasms

HR+/HER2- Advanced Breast Cancer

Carcinoma, Neuroendocrine

Clinical Trials

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

MOMENTUM-1

EVOLVE-BDT

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

LEVER

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

GERTRUDE

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

MOST plus

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

RAD001 in Recurrent Endometrial Cancer Patients

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

ELUMEN

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

MANTA

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

EVACEL

Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome

MEGALiT

abemaSNF1/3

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

EVENET

Everolimus for Children With Recurrent or Progressive Ependymoma

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

BCTOP-L-M01

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

DCLNF1

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

ROME

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

PEARL

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin